Clinical Trial

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 8, 2025 (before its estimated June 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, prospective, randomized controlled clinical study comparing the efficacy and safety of CLAG+VEN and CLAG regimens in relapsed/refractory(r/r) AML.
Trial Details
NCT Number NCT06763666
Lead Sponsor Nanfang Hospital, Southern Medical University
Collaborators: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou No.12 People's Hospital, Guangzhou Panyu Central Hospital, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou First People's Hospital, Foresea Life Insurance Guangzhou General Hospital, Guangdong Second Provincial General Hospital, Jiangmen Central Hospital, Shantou Central Hospital, Maoming People's Hospital, First Affiliated Hospital of Guangxi Medical University, Hainan General Hospital, Dongguan People's Hospital, Tungwah Hospital of Sun Yat-Sen University, Shenzhen Hospital of Southern Medical University, Central People's Hospital of Zhanjiang, ZhuHai Hospital, Shenzhen Second People's Hospital, Zhongshan People's Hospital, Guangdong, China, LiuZhou People's Hospital, First People's Hospital of Foshan, Southern Medical University, China, Affiliated Hospital of Guangdong Medical University, Guilin Medical University, China, Yuebei People's Hospital, Huizhou Municipal Central Hospital, Second Affiliated Hospital of Guangzhou Medical University, Peking University Shenzhen Hospital
Conditions Relapsed/Refractory AML
Enrollment 172 participants
Start Date 2025-02
Primary Completion 2025-06 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-01-08